Home
Clinical Resources Search
PQI: Daratumumab (Darzalex®) for Multiple Myeloma

Daratumumab (Darzalex®) for Multiple Myeloma

Download PQI pdf 0.24MB

Last Updated: May 22, 2024

By: Lauren Trisler, PharmD, BCOP

About this PQI

Daratumumab is an anti-CD38 monoclonal antibody (mAb) FDA approved for use in a range of multiple myeloma patients including first line, transplant-ineligible, and refractory.1 This PQI will provide guidance for optimal administration and management of both daratumumab infusions and subcutaneous formulation.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Hematological Malignancies Multiple Meloma (MM) Multiple Myeloma

PQI

Frequently Searched

Supported by

Daratumumab (Darzalex®) for Multiple Myeloma

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Eflapegrastim-xnst (Rolvedon) for Chemotherapy-Induced Neutropenia

PQI: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI: Talectrectinib (Ibtrozi) for the Management of ROS1+ Advanced NSCLC

PQI: Zanidatamab-hrii (Ziihera) for the Management of Biliary Tract Cancer

PQI in Action: Abiraterone acetate (Yonsa®) Patient Selection and Management

PQI in Action: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI in Action: Fruquintinib (Fruzaqla®)

PQI in Action: Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer – 2

S9 E4: Advancing Pharmacogenomics in Oncology

S9 E3: Firefighter Health & Cancer Prevention

S9 E2: Love Languages in Cancer Care

S9 E1: Head & Neck Cancer Care: Clinical Progress & Compassionate Practice

Readiness Tracker

Treatment Support Kit: Elranatamab

Treatment Support Kit: Mirdametinib

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

S7 Ep 8: Sickle Cell Disease Insights

PQI: Selinexor (Xpovio®) Patient Management

PQI: Ixazomib (Ninlaro®) In the Treatment of Multiple Myeloma

PQI: Isatuximab-irfc (Sarclisa®) Regimens in 1q21 gain/amplification Relapsed/ Refractory Multiple Myeloma

PQI: Isatuximab-irfc (Sarclisa®) In Patients with Relapsed/Refractory Multiple Myeloma

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

PQI in Action: ClonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma

PQI: Eflapegrastim-xnst (Rolvedon) for Chemotherapy-Induced Neutropenia

S9 E4: Advancing Pharmacogenomics in Oncology

S9 E3: Firefighter Health & Cancer Prevention

PQI in Action: Abiraterone acetate (Yonsa®) Patient Selection and Management